araag2/TREC_Precision-Medicine huggingface dataset:
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Chest Imaging, Breath, and Biomarkers in a Screening Trial

Summary: The investigators would like to see if lung cancer screening with chest x-rays,computer aided detection (CAD)and a lose dose CT scan can detect lung cancer in early stages when it is more responsive to treatment. The investigators would also like to see if early detection will reduce the incidence of symptomatic advanced lung cancer compared to no screening in former and current smokers with or without a family history of lung cancer who are 40-75 years old.

Detailed description: The fight against lung cancer is waged on three major fronts: prevention, detection and treatment. Our goal is to determine if chest x-rays,computer aided detection (CAD)and a CT scan can detect disease earlier when treatment is more effective. If we improve the detection of disease, we will see if screening reduces the incidence of symptomatic advanced lung cancer relative to no screening in people at high risk to develop lung cancer.

Eligibility: Inclusion Criteria:
  -  ages 40-75 years
  -  If ages 40-59, then one of the following criteria needs to be met:
  -  Current or ex-smoker with >25 pack years and a family history of lung cancer(parent or sibling) OR
  -  current or ex-smoker with > 25 pack years and COPD OR
  -  current or ex-smoker with a > 35 pack year history
  -  If ages 60-75, then one of the following additional criteria needs to be met:
  -  Current or ex-smoker with >25 pack years and a family history of lung cancer (parent or sibling) OR
  -  Current or ex-smoker with >25 pack years and COPD OR
  -  Current or ex-smoker with a >30 pack year history
  -  Subject is able to return to Cleveland Clinic for annual follow-up screening
  -  Subject is willing to sign a medical release form
  Exclusion Criteria:
  -  Current health requires oxygen
  -  Have had a chest x-ray or CT of the chest within the last 6 months
  -  Previous pneumonectomy
  -  Lobectomy of the lung within the last 5 years
  -  Diagnosed malignancy within the last 5 years, excluding non-melanoma skin cancer, carcinoma in situ of the cervix and localized prostate cancer
  -  A medical condition that would prevent treatment for lung cancer
  -  Within the last 6 weeks, one of the following has occured:
  -  A new cough or chronic cough that has gotten worse
  -  Either new shortness of breath, or any worsening of shortness of breath
  -  A cough producing blood
  -  Constant chest pain
  -  Respiratory infection, pneumonia, or cold
  -  Unintentional and unexplained weight loss greater than 5% of total body weight

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Summary: This open-label, multi-center study will evaluate the progression-free survival and safety of erlotinib in participants with locally advanced or metastatic non-small cell lung cancer with activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR). Participants will receive daily oral doses of erlotinib until disease progression or unacceptable toxicity.


Eligibility: Inclusion Criteria:
  -  Diagnosis of locally advanced or metastatic non-small cell lung cancer with activating mutations in the tyrosine kinase domain of the EGFR
  -  Measurable disease according to RECIST
  -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  -  Life expectancy greater than or equal to (>/=) 12 weeks
  -  Adequate hematological, liver and renal function
  -  Participants with asymptomatic and stable cerebral metastases receiving medical treatment
  Exclusion Criteria:
  -  Previous chemotherapy or treatment against EGFR for metastatic disease
  -  Treatment with an investigational agent less than 3 weeks before enrollment
  -  History of neoplasm other than non-small cell lung cancer (except carcinoma in situ of the uterine cervix, basal cell skin carcinoma, or prostate carcinoma)
  -  Participants with symptomatic cerebral metastases
  -  Any significant ophthalmologic abnormality
  -  Unstable systemic disease
  -  Coumarins use
  -  Evidence of any other disease, neurological or metabolic dysfunction, physical examination or laboratory finding contraindicating the use of an investigational drug
  -  Participants with pre-existing parenchymal lung disease such as pulmonary fibrosis, lymphangiosis carcinomatosis
  -  Participants with known infection with human immunodeficiency virus (HIV), Hepatitis B (HBV), Hepatitis C (HCV)

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Free Fatty Acid Metabolite Biomarkers for Cancer

Summary: Surgical removal of tumor at an early stage remains the primary treatment for most cancers. However, there is currently no reliable screening blood test for detection of lung, colon, or breast cancer. The Specific Aims are to: 1) assess the diagnostic accuracy of six FFA metabolites to detect lung and colon cancer in surgical patients; 2)determine the rate and extent to which FFA metabolites decrease over time after surgery for lung and colon cancer; and, 3)determine the positive and negative predictive values and overall test accuracy for diagnostic prostate and breast biopsies.


Eligibility: Inclusion Criteria:
  -  potential breast cancer
  -  patients who have early stages of breast cancer prior to surgery potential prostate cancer lung cancer colon cancer
  Exclusion Criteria:
  -  1) Patients will be excluded from enrollment if they have severe liver disease (ALT three times the upper limit of normal). Patients will also be excluded who have taken aspirin or COX inhibitors within 48 hours of surgery. 2) Patients will be excluded if a pathologic diagnosis is already available,from a previous needle biopsy (coordinator will remain blinded). 3) Patients will be excluded have received pre-procedure chemotherapy or radiotherapy

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Lung Cancer Screening Study With Low-dose CT Scan and Blood Biomarker

Summary: Lung cancer is the number one cancer killer in the USA. Early stage lung cancer is asymptomatic. Most patients with lung cancer are usually symptomatic at diagnosis and already have advanced stage disease. Low dose CT screening (LDCT) for high risk individuals has recently been shown to decrease lung cancer mortality by 20%. However, 4 out of 5 lung cancer deaths are not prevented with LDCT screening alone.

Detailed description: In this trial, the addition of a blood biomarker test is being combined with early LDCT to determine if screening with combination may result in detection of more lung cancer at an earlier stage of disease.The study will also assess if the blood test is able to detect lung cancers in high risk individuals when the LDCT is negative for cancer. There will be health-economic costs included in the final analysis of study data.

Eligibility: Inclusion Criteria:
  -  Smokers or former smokers
  -  At least 20 pack year history of smoking
  -  Ages 50 - 75
  Exclusion Criteria:
  -  Had a CT scan of chest within last 24 months
  -  History of any cancer within 10 yrs (except skin cancer or cervical cancer)
  -  A serious illness that decreases life expectancy to less than 5 years
  -  Any current use of Oxygen
  -  Uncontrolled congestive heart failure or cardiac arrhythmia that would prevent surgery for a lung lesion
  -  Severe COPD or dyspnea that would prevent lung surgery or stereotactic body radiotherapy

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: The Medication Experience Study

Summary: The purpose of this study is to evaluate whether participation in an Internet-based intervention helps improve medication use.


Eligibility: Inclusion Criteria:
  -  Any male or female 18 years or older, filling prescriptions for oral medications for hypertension, high cholesterol, diabetes, or depression at the Downtown Health Plaza, Piedmont Plaza, or Cancer Center Pharmacies.
  Exclusion Criteria:
  -  Inability to complete Internet surveys due to inadequate Internet access, not understanding a survey written in English, or lack of computer skills.
  -  Patient does not intend to continue using the same WFBMC-affiliated pharmacy for the next 12 months.

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Mechanisms of Immunosurveillance for Lung Cancer

Summary: The purpose of this research study is to investigate the differences in "natural killer (NK) blood cells, a type of white blood cell that fights infection in the body, among different types of patients that have lung surgery. The four different groups of patients are:
  -  smokers with lung cancer
  -  smokers without lung cancer
  -  non-smokers with lung cancer
  -  non-smokers without lung cancer.

Detailed description: Research has shown that different strains of mice possess varying susceptibility to lung cancer. C3H and C57BL6 mice are highly resistant to lung cancer, whereas A/J and 129 mice are very susceptible to lung cancer. Data from our lab shows that the mice have different numbers of natural killer (NK) cells as well as different characteristics of those cells. C3H and C57BL6 mice have higher numbers of NK cells as well as higher expression of CD11b, whereas A/J and 129 mice have lower numbers and lower expression.
  These findings justify parallel investigation of NK cells in human populations resistant and susceptible to lung cancer. Through blood samples, circulating NK cells can be counted and phenotypically analyzed. Smoking can be used as a factor to establish lung cancer risk. Additionally, non-smokers suffering from lung cancer provide an opportunity to investigate whether lung cancer patients have lower abundance of NK cells and lesser expression of CD11b, independent of the effects of smoking.
  Objective:
  The main goal of this study is to investigate the quantitative and phenotypic differences in circulating NK cells among human populations. Participants will be classified as heavy smokers (HS), non-smokers (NS), those suffering from lung cancer (LC), and those free from lung cancer (NC).
  Hypothesis #1: NS/LC participants will have fewer NK cells and lower expression of CD11b compared to HS/NC and NS/NC participants.
  Hypothesis #2: NS/LC participants will have more numerous NK cells and higher expression of CD11b compared to HS/LC participants.

Eligibility: Inclusion Criteria:
  -  Age equal or greater to 18 years
  -  Ability to read and write in English
  -  Able to participate in the informed consent process
  Exclusion Criteria:
  -  Known active hepatitis B, hepatitis C, or HIV/AIDs (found in medical record)
  -  Chemotherapy or radiation therapy within 3 months of enrollment
  -  Type 1 Diabetes Mellitus
  -  Rheumatoid arthritis, Lupus, Multiple Sclerosis, or any other autoimmune disease as deemed necessary for exclusion by the Principal Investigator
  -  Previous organ transplant
  -  Blood transfusion within 3 months prior to enrollment
  -  Any previous cancer, excluding a previous lung cancer
  -  Steroid use within 4 weeks of enrollment

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: CROSSROAD II: Activating Rural Clinics and Women With Disabilities to Improve Cancer Screening

Summary: The goal of this project is to develop and pilot test an innovative approach for overcoming barriers to cancer screening among women with physical disabilities (WWD) in rural Oregon. Many studies have shown that people with disabilities receive fewer indicated cancer screening services and are more likely to have poor cancer-related outcomes, such as late stage at diagnosis, compared to those without disabilities.


Eligibility: Inclusion Criteria:
  -  Female
  -  Aged 50-75 at time of screening
  -  No personal history of breast, cervical or colorectal cancer
  -  Not being up-to-date with at least one screening test for breast, cervical, and/or colorectal cancer
  -  Meets the study definition of disability per screening survey OR
  -  Be a woman who does not meet the definition of disability per screening survey, but has been matched to a participant who does (observation group).
  Exclusion Criteria:
  -  Non female
  -  Personal history of breast, cervical, or colorectal cancer
  -  Coming into clinic for an urgent care issue

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Efficacy of EGFR TKIs in Patients With Rare EGFR-mutated NSCLC

Summary: Lung cancer is the leading cause of cancer-related death worldwide and is well known to remain a major health problem. Non-small-cell lung cancer (NSCLC) constitutes more than 80% of all the cases of lung cancer.
  Today, NSCLC can be defined by various molecular criteria. Especially, somatic mutations within the epidermal growth factor receptor (EGFR) gene itself were discovered in a subset of NSCLC patients.
  Two activating EGFR mutations are in-frame deletion in exon 19 and the substitutions for L858R in exon 21, which account for 85% of all clinically important mutations related to EGFR TKI sensitivity.
  Besides two activating EGFR mutations, other EGFR mutations in NSCLC have been discovered. G719 and L861 are reported to have intermediate sensitivity to EGFR TKI. And in-frame insertions within exon 20 and T790, which are known to be resistant to EGFR TKIs.
  However, there are still other EGFR mutations such as E709 and S768 as well as doublet EGFR mutations are also observed. These rare mutations have not been fully described and data on their correlation with response to EGFR-TKIs are still unclear.
  Research hypothesis Rare EGFR mutations of unknown clinical significance in NSCLC patients, which are distinguish from mutations such as deletion in exon 19, L858 and insertion in exon 20, have some possibility of EGFR TKI sensitivity.
  Rationale for conducting this study It has an opportunity to be shown the efficacy of EGFR TKIs in patients with rare EGFR mutation in large number of patients in Korea (Asia) during the short period.


Eligibility: Inclusion Criteria:
  1. Histological confirmed non-small cell lung cancer (NSCLC), Stage IIIB or stage IV, between January 1, 2008 to December 31, 2011
  2. Confirmed EGFR rare mutations (EGFR mutation except both exon 19 deletion and exon 21 L858R) using direct DNA sequencing
  3. Experiences of treatment with EGFR TKIs.
  4. at least one measurable and/or evaluable lesion according to RECIST criteria (version 1.1)
  Exclusion Criteria:Subjects should not enter the study if any of the following exclusion criteria are fulfilled: EGFR wild type, EGFR exon 19 deletion alone, EGFR L858R alone

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis

Summary: To detect resistance gene from serially collected plasma DNA in non-small cell lung cancer harbouring EGFR activating mutation who are being treated with EGFR TKIs by using castPCR method.


Eligibility: Inclusion Criteria:
  -  1. Histologically confirmed NSCLC 2. Aged of or older than 20 years 3. ECOG performance status 0-2 4. Adequate hematological, renal, hepatic function 5. Patients with tumors harboring EGFR mutation (del 19 or L858R mutation) 6. Patient who are about to be treated with EGFR TKI (gefitinib, erlotinib or other EGFR TKI) 7. At least more than one measurable disease 8. Informed consent
  Exclusion Criteria:
  -  1. Active infection 2. Active bleeding

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Prevalence and Incidence of Central Airway Obstruction in Advanced Lung Cancer

Summary: Lung cancer may cause central airway obstruction through several different mechanisms (invasion by the primary tumor, invasion by metastatic lymph nodes, airway metastasis).
  The aim of the present study is to determine the prevalence at the time of diagnosis, the incidence at 1 year from the diagnosis, and the predictors of central airway obstruction associated with advanced lung cancer.


Eligibility: Inclusion Criteria:
  -  Advanced lung cancer with indication for chemotherapy or chemotherapy + radiation therapy
  Exclusion Criteria:
  -  Age < 18 year
  -  Pregnancy
  -  Refusal to sign informed consent

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Evaluation of Endobronchial Ultrasound (EBUS) for Staging Lung Cancer

Summary: This study will compare two different methods of staging lung cancer to determine whether endobronchial ultrasound (EBUS) staging of mediastinal lymph nodes will provide good diagnostic yield in detecting lung cancer, when compared to current methods of a staging bronchoscopy and cervical mediastinoscopy.


Eligibility: Inclusion Criteria:
  Patients, > 18 years of age,
  Gender- Males and Female
  Diagnosis of Non Small Cell Lung Cancer.
  Patients who have consented on an Ottawa Hospital consent form to undergo a mediastinoscopy procedure or EBUS-TBNA, and a Positron emission tomography (PET) of the chest for lung cancer staging.
  Exclusion Criteria:
  Females who are pregnant (or found to be pregnant) during the course of this research study.
  Patients who do not provide their Ottawa Hospital consent to undergo a staging bronchoscopy , cervical mediastinoscopy or EBUS-TBNA.

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Risk Adapted SABR(SABR) in Stage I NSCLC And Lung Metastases

Summary: This study is designed to evaluate the safety of Stereotactic Ablative Radiotherapy (SBRT) in selected patients with stage I Non Small Cell Lung Cancer (NSCLC) or metastatic lung cancer to demonstrate the feasibility and risks of using an ablative dose-adapted scheme with FFF beams. Other aims are To evaluate the incidence of acute and late complications; To evaluate tumour response to local radiation therapy by means of CT, PET/TC and MRI and To evaluate the impact of local therapy on overall and disease-free survival.

Detailed description: The intervention (dose and fractions) depends on topographical parameters: lung disease (primary, peripheral nodes or mediastinal nodes), distance to chest wall, tumour size and distance to main bronchus.

Eligibility: Inclusion Criteria:
  -  Histologically-confirmed primary lung cancer or lung metastasis from another primary tumour or positive PET/CT suggestive for primary tumour(SUV MAX> 4).
  -  Tumour size < 5 cm in diameter prior to treatment.
  -  Medically inoperable patients as determined by the multidisciplinary thoracic tumour board, or medically operable patients who refuse surgery.
  -  Life expectancy of >12 months.
  -  Criterion for medical inoperability include:
  Overall clinical assessment at the UCLA thoracic tumour board. Reduced Pulmonary Function (FEV1, DLCO, etc) based on one major or two minor criterion as described below: Minor Criteria: Age > 75, FEV1 51- 60% predicted, or FEV1 1-1.2L, DLCO 51%-60% predicted, pulmonary hypertension, poor left ventricular function (EF < 40% or less), resting or exercise arterial pO2 < 55 mmHg, and pCO2 > 45 mmHg.
  -  Age > 18 years.
  -  KPS > 70.
  -  Barthel score >40
  -  Baseline computed tomography scans of the chest, pulmonary test function, and positron emission tomography no more than 2 months before treatment.
  -  If a woman is of childbearing potential, a negative urine or serum pregnancy test must be documented.
  -  Ability to understand and the willingness to sign a written informed consent.
  Exclusion Criteria:
  -  Prior thoracic radiation treatment wich dose contribution can be expected in the new SBRT plan.
  -  More than two lesions per lobe.
  -  Active infections requiring systemic antibiotics.
  -  Age <18 years old.
  -  KPs < 70.
  -  Barthel Total Score < 40.

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: CTP Imaging of Lung Cancer

Summary: Investigators hope to learn more about how to use computed tomography (CT) scans to measure blood flow in lung tumors and how it may change in response to treatment. This measurement technique is called computed tomography perfusion (CTP). CT scanners use X-rays to produce 3-dimensional images of the body.
  Currently, doctors determine the response to treatment by measuring the size of the tumor. Investigators are trying to find out if measuring the blood flow in the tumor is equal to or better than measuring the size of the tumor.

Detailed description: This is an experimental study of CT perfusion (CTP) imaging in subjects with non-small cell lung cancer. The objectives of this study are to demonstrate the feasibility of CT blood flow measurements in lung cancer, to develop a foundation for the use of CT blood flow measurements in lung cancer to assess the response to treatment, and to develop an optimized CTP imaging protocol for evaluating blood flow in solid body tumors. In this study, tumor blood flow will be evaluated at baseline and follow-up routine CT examinations of patients with non-small cell lung cancer, and the response of tumor blood flow will be recorded as a secondary endpoint. This research study will entail two study visits - one required and one optional - which will coincide with regularly scheduled standard of care CT scans.

Eligibility: Inclusion Criteria:
  adult patients with non small cell lung cancer who receive, or are considered for, systemic therapy
  Exclusion Criteria:
  renal failure pregnancy known contrast allergy

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Circulating Tumor Cells in Non-Small Cell Lung Carcinoma

Summary: The purpose of this study is to establish the circulating tumor cell (CTC) assay as a surrogate for tissue diagnosis of suspected primary lung cancer. This is done through evaluating clinical and molecular markers to stratify the outcome/survival in patients with thoracic malignancies treated at Yale University/Yale-New Haven Hospital, University of California San Diego/Moores Cancer Center, Billings Clinic Cancer Center.


Eligibility: Inclusion Criteria:
  -  Suspected lung cancer
  -  Planned to undergo tissue biopsy. Tissue biopsy does not need to be limited to an intrathoracic structures. Biopsies of the supraclavicular lymph nodes are allowed
  -  Age >18
  Exclusion Criteria:
  -  Patients with history of a separate (not a primary lung cancer) malignancy within past two years.
  -  Recent history (past two weeks) of trauma (INCLUDING diagnostic surgery, biopsy, etc)
  -  Prior lung cancer treatment chemotherapy, radiation, surgery, etc. in past two years.
  -  Inability to provide informed consent.
  -  Hgb less than 8.

Relevance to patient case: not relevant